Ozmosi | alfa1 antitrypsin Drug Profile
Contact Us
Drug Profile
Using advanced filters...
Advanced Search [+]

alfa1 antitrypsin

Alternative Names: alfa1 antitrypsin
Clinical Status: Inactive
Latest Update: 2026-05-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action:

Novel Mechanism: No

Modality: Unknown

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Latvia | Lithuania | Netherlands | Norway | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | United States | Uruguay

Approved Indications: None

Company: CSL Behring
Company Location: Eastern America
Company Founding Year: 1904
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for alfa1 antitrypsin

Countries in Clinic: Germany, Italy, Spain

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Graft vs Host Disease|alpha 1-Antitrypsin Deficiency

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

2024-511164-92-00

 CSL964_2001

P3

Recruiting

Graft vs Host Disease

2027-05-06

2025-05-02

Treatments

2024-515894-80-00

 PPRO24-001

P3

Not yet recruiting

alpha 1-Antitrypsin Deficiency

2026-02-25

2025-05-02

Treatments

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions